Literature DB >> 10586308

Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.

J van der Weide1, L S Steijns.   

Abstract

The cytochrome P450 (CYP) enzyme system is involved in the metabolism and elimination of numerous widely used drugs. The capacity of this system varies from one person to another, leading to variable drug excretion rates and intersubject differences in the final serum drug concentrations. For this reason, therapeutic response and side-effects vary widely between patients treated with the same dose of drug. The intersubject variability in metabolic rate is largely determined by genetic factors. Some CYP enzymes, including CYP2D6 and CYP2C19, are genetically polymorphic. Several mutant alleles have been described, Environmental factors such as smoking, diet and co-administration of medications might also influence the CYP enzyme activity. By the use of genotyping or phenotyping methods every individual can be classified as either a poor, an intermediate, an extensive or an ultrarapid metabolizer. If this could be performed prior to drug therapy, the knowledge could be applied to drug selection and dose adjustment in order to reach therapeutic serum drug levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586308     DOI: 10.1177/000456329903600604

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  20 in total

1.  Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective.

Authors:  Koji Takeda
Journal:  Ther Adv Med Oncol       Date:  2013-09       Impact factor: 8.168

2.  Isolation and characterization of the CYP2D6 gene in Felidae with comparison to other mammals.

Authors:  Tamara Schenekar; Kathrin A Winkler; Jennifer L Troyer; Steven Weiss
Journal:  J Mol Evol       Date:  2010-12-28       Impact factor: 2.395

Review 3.  Pharmacogenetics in health-care practice.

Authors:  der Zee Anke-Hilse Maitland-van; Olaf H Klungel; Anthonius de Boer
Journal:  Pharm World Sci       Date:  2004-10

4.  CYP2D6 polymorphisms in patients with porphyrias.

Authors:  Jimena V Lavandera; Victoria E Parera; Alcira Batlle; Ana María Buzaleh
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

Review 5.  Pharmacogenetics of Opioid Use Disorder Treatment.

Authors:  Richard C Crist; Toni-Kim Clarke; Wade H Berrettini
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

6.  The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications.

Authors:  Jan van der Weide; John W J Hinrichs
Journal:  Clin Biochem Rev       Date:  2006-02

Review 7.  Toward precision medicine in pediatric population using cytochrome P450 phenotyping approaches and physiologically based pharmacokinetic modeling.

Authors:  Gaëlle Magliocco; Frédérique Rodieux; Jules Desmeules; Caroline Flora Samer; Youssef Daali
Journal:  Pediatr Res       Date:  2019-10-10       Impact factor: 3.756

8.  A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.

Authors:  Doaa A Elsherbiny; Sara A Asimus; Mats O Karlsson; Michael Ashton; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-03-19       Impact factor: 2.745

9.  Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706).

Authors:  Makoto Tahara; Naomi Kiyota; Junki Mizusawa; Kenichi Nakamura; Ryuichi Hayashi; Tetsuo Akimoto; Yasuhisa Hasegawa; Shigemichi Iwae; Nobuya Monden; Kazuto Matsuura; Hirofumi Fujii; Yusuke Onozawa; Akira Homma; Akira Kubota; Haruhiko Fukuda; Masato Fujii
Journal:  Cancer Sci       Date:  2015-04-01       Impact factor: 6.716

10.  SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions.

Authors:  Saskia Preissner; Katharina Kroll; Mathias Dunkel; Christian Senger; Gady Goldsobel; Daniel Kuzman; Stefan Guenther; Rainer Winnenburg; Michael Schroeder; Robert Preissner
Journal:  Nucleic Acids Res       Date:  2009-11-24       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.